Pulmonary vascular disease & thromboembolism
Occult cancer in patients with unprovoked venous thromboembolism: Rationale, design, and methods of the VaLRIETEs study and the SOME-RIETE trial
Study context
- Population
- Patients with unprovoked symptomatic venous thromboembolism (VTE)planned enrolment · ValRIETE (planned) 1,550 · SOME-RIETE, RIETE score ≥3 (planned) 650
- Planned comparison
- Limited screening with limited screening plus whole body 18F-FDG PET/CT
- Primary endpoint
- cancer diagnosis
- Follow-up
- Within 3 months after VTE event
Methodological detailsSOME-RIETE, adaptive design permits a sample size increase depending on the results of the predefined interim analysis
- SOME-RIETE
- Adaptive design permits a sample size increase depending on the results of the predefined interim analysis
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Study conduct
- ValRIETE recruitment began
- December 2022
- Secondary outcomes include cancer diagnosis and mortality at 12 months
Original publication
Occult cancer in patients with unprovoked venous thromboembolism: Rationale, design, and methods of the VaLRIETEs study and the SOME-RIETE trial. Am Heart J. Published 17 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →